Eli Lilly launched “TuneLab,” an AI/ML platform that gives selected biotechs access to drug-discovery models trained on years of Lilly research data. Initial public partners include Circle Pharma and insitro. Lilly says the first release reflects more than $1B worth of internal data investment. Lilly says biotechs run its models locally on their own infrastructure…
AI drug discovery space consolidates with $688M Recursion and Exscientia merger
Recursion Pharmaceuticals and Exscientia, two of the most prominent AI-driven drug discovery companies, are merging. The deal, which the firms expect to be official in early 2025, would create a portfolio of clinical and near-clinical programs with an expected 10 clinical readouts over the the next 18 months with “peak sales opportunities in excess of…